Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of subcutaneous isatuximab plus carfilzomib and dexamethasone in adults with relapsed and/or refractory multiple myeloma
CTR20252554Phase 2Active
- Sponsor
- Sanofi
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab, carfilzomib, dexamethasone in multiple myeloma (MM), sponsored by Sanofi. Started Sep 2025; status: active.
02
Drugs
isatuximabcarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20252554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252554.